| Literature DB >> 25093114 |
E A Trifonova1, T V Gabidulina2, N I Ershov3, V N Serebrova4, A Yu Vorozhishcheva5, V A Stepanov1.
Abstract
Preeclampsia is one of the most severe gestational complications which is one of the leading causes of maternal and perinatal morbidity and mortality. A growth in the incidence of severe and combined forms of the pathology has been observed in recent years. According to modern concepts, inadequate cytotrophoblast invasion into the spiral arteries of the uterus and development of the ischemia-reperfusion syndrome in the placental tissue play the leading role in the development of preeclampsia, which is characterized by multipleorgan failure. In this regard, our work was aimed at studying the patterns of placental tissue transcriptome that are specific to females with PE and with physiological pregnancy, as well as identifying the potential promising biomarkers and molecular mechanisms of this pathology. We have identified 63 genes whose expression proved to differ significantly in the placental tissue of females with PE and with physiological pregnancy. A cluster of differentially expressed genes (DEG) whose expression level is increased in patients with preeclampsia includes not only the known candidate genes that have been identified in many other genome-wide studies (e.g., LEP, BHLHB2, SIGLEC6, RDH13, BCL6), but also new genes (ANKRD37, SYDE1, CYBA, ITGB2, etc.), which can be considered as new biological markers of preeclampsia and are of further interest. The results of a functional annotation of DEG show that the development of preeclampsia may be related to a stress response, immune processes, the regulation of cell-cell interactions, intracellular signaling cascades, etc. In addition, the features of the differential gene expression depending on preeclampsia severity were revealed. We have found evidence of the important role of the molecular mechanisms responsible for the failure of immunological tolerance and initiation of the pro-inflammatory cascade in the development of severe preeclampsia. The results obtained elaborate the concept of the pathophysiology of preeclampsia and contain the information necessary to work out measures for targeted therapy of this disease. ;Entities:
Keywords: gene expression; genome-wide analysis; microarrays; placenta; preeclampsia; transcriptome
Year: 2014 PMID: 25093114 PMCID: PMC4115229
Source DB: PubMed Journal: Acta Naturae ISSN: 2075-8251 Impact factor: 1.845
Characteristics of the examined groups
| Parameters | PE,N = 10 | Control group | p-value* |
|---|---|---|---|
| Mean age, years | 26 ± 2 | 28 ± 3 | 0.241 |
| Mean weight, kg | 60 ± 7 | 62 ± 6 | 0.324 |
| Body mass index, BMI | 23 ± 4 | 23 ± 3 | 0.832 |
| The mean maximum systolic blood pressure, mm Hg | 162 ± 19 | 121 ± 3 | 0.0001 |
| The mean maximum diastolic blood pressure, mm Hg | 104 ± 13 | 80 ± 4 | 0.0001 |
| Delivery time, weeks | 38 ± 1 | 40 ± 2 | 0.009 |
| Birth weight, g | 2783 ± 560 | 3549 ± 345 | 0.004 |
| Length at birth, cm | 50 ± 4 | 53 ± 2 | 0.021 |
| Premature birth, % | 50 | 0 | 0.012 |
| Chronic diseases, % | 60 | 50 | 0.575 |
* The significance level was determined by comparing the groups using the Mann-Whitney test or Fisher’s exact test.
Threshold cycle values and the calculated number of DNA copies in the model samples after real-time PCR
| No | Change in | FC | FDR | Gene | Chromosome | Gene product | Primary functions* |
|---|---|---|---|---|---|---|---|
| 1 | ↑ | 1.054 | 0.0007 | LEP | 7 | Leptin | The gene encodes the protein which is secreted by |
| 2 | ↓ | 3.84 | 0.0001 | HS.201441 | 13 | Long non-coding RN A 284 | According to the analysis of EST-libraries, tissuespecific |
| 3 | ↑ | 2.95 | 0.0000 | BHLHE40 | 3 | Transcription factor including | Transcription factor modulating chondrogenesis |
| 4 | ↑ | 2.93 | 0.0031 | ANKRD37 | 4 | Ankyrin 37 repeat domain | The encoded protein contains four ankyrin repeats, |
| 5 | ↑ | 2.91 | 0.0067 | SIGLEC6 | 19 | Immunoglobulin-like lectin 6, | Immunoglobulin-like lectins that bind to sialic acids |
| 6 | ↑ | 2.64 | 0.0006 | ZNF175 | 19 | Zinc finger protein 175 | Negative regulation of the expression of various |
| 7 | ↑ | 2.43 | 0.0031 | CCSAP (C1orf96) | 1 | Protein localized in centriole, cilia | Presumably plays a role in embryonic development |
| 8 | ↑ | 2.43 | 0.0050 | GPT2 | 16 | Alanine aminotransferase 2; | Catalyzes the reversible transamination between |
| 9 | ↑ | 2.39 | 0.0050 | RDH13 | 19 | Retinol dehydrogenase 13 | Catalyzes oxidation and reduction of retinoids and |
| 10 | ↑ | 2.36 | 0.0006 | BCL6 | 3 | Transcription factor – zinc finger | Contains N-terminal POZ/BTB-domain and is a |
| 11 | ↑ | 2.33 | 0.0056 | PLIN2 | 9 | Perilipin 2, lipid droplet protein | Perilipin function in basic cells is to stabilize the |
| 12 | ↑ | 2.31 | 0.0174 | NRIP1 | 21 | Nuclear factor RIP140 | Modulates the transcriptional activity of steroid |
| 13 | ↑ | 2.18 | 0.0407 | HILPDA (C7orf68) | 7 | Hypoxia-induced protein 2 (open | The gene encodes hypoxia-induced factor 2, which |
| 14 | ↑ | 2.18 | 0.0006 | SYDE1 | 19 | GTPase-activating protein, | This protein belongs to the Rho GTPase family, which |
| 15 | ↑ | 2.06 | 0.0050 | CORO2A | 9 | Coronin 2A | Belongs to actin-binding protein family, which |
* Information from the GeneCards database (http://www.genecards.org/) including addendum.
List of differentially expressed genes (FDR < 0.1; FC ≤= 1.5) in="" moderate="" to="" severe="" preeclampsia=""
| Gene | Change in gene | FC | FDR | Gene product |
|---|---|---|---|---|
| HSPA1A | ↑ | 6.44 | 0.079549 | Heat shock protein 70, HSP70-1A |
| BAG3 | ↑ | 2.14 | 0.073131 | Bcl-2-associated athanogene 3 |
| SNHG8 | ↑ | 1.78 | 0.04105 | Small nucleolar RN A 8 |
| LOC729660 | ↓ | 2.63 | 0.010437 | No data |
| LOC728457 | ↓ | 2.43 | 0.010437 | No data |
| APOC1 | ↓ | 2.28 | 0.04433 | Apolipoprotein C1 |
| LOC401357 | ↓ | 2.27 | 0.010399 | No data |
| LOC100128326 | ↓ | 1.92 | 0.079549 | No data |
Main biological processes that involve differentially expressed genes characteristic of severe preeclampsia
| Categories of biological processes | Gene | p* |
|---|---|---|
| Processing and presentation of peptides or polysaccharide antigens via class II MHC molecules (GO:0002504) | HLA-DPA1, CD74, HLA-DMA, HLA-DRA | 0.0421 |
| Processing and presentation of exogenous peptide antigens (GO:0002478) | HLA-DMA, CD74, HLA-DRA | 0.0453 |
| Chaperone-mediated protein folding (GO:0051085) | ERO1L, HLA-DMA, CD74 | 0.0467 |
| De novo post-translational protein folding (GO:0051084) | ERO1L, HLA-DMA, CD74 | 0.0478 |
| Reactions of unfolded protein molecules (GO:0006986) | ERO1L, HSPH1,HSPA1A, HERPUD1 | 0.0489 |
* Significance level including Benjamin-Hochberg multiple testing correction, which characterized the accuracy of the assignment of this set of genes to a certain biological process.
Differentially expressed genes identified in this study whose association with preeclampsia has been previously shown in studies focused on the placental tissue transcriptome
| No | Gene | Gene product | FC | Significance | Ethnic populations | Reference |
|---|---|---|---|---|---|---|
| 1 | LEP | Leptin | 10.94 | < 0.0001* | Japanese | [ |
| 8.58 | 0.036* | Chinese | [ | |||
| 40.11 | 1.35 × 10-9 | Caucasian | [ | |||
| 5.52 | 0.0020 | Caucasian | [ | |||
| 108.9 | < 0.0001 | Caucasian | [ | |||
| 4.4 | < 0.0001 | Korean | [ | |||
| ≥ 1.5 | < 0.05 | Chinese | [ | |||
| 11.79 | < 0.01* | American | [ | |||
| 2 | BCL6 | Transcription factor – zinc finger | 1.78 | 0.0154 | Caucasian | [ |
| 2.02 | 0.0024 | Japanese | [ | |||
| 2.24 | 3.58 × 10-5 | Caucasian | [ | |||
| 2.60 | < 0.01* | American | [ | |||
| ≥ 1.5 | < 0.05 | Chinese | [ | |||
| 3 | SIGLEC6 | Immunoglobulin-like lectin 6, which | - | 0.02* | American | [ |
| 2.13 | 0.001 | Caucasian | [ | |||
| 2.73 | < 0.01* | American | [ | |||
| ≥ 1.5 | < 0.05 | Chinese | [ | |||
| 4.5 | 0.019 | Caucasian | [ | |||
| 4 | RDH13 | Retinol dehydrogenase13 | - | 3.86 × 10-8* | American | [ |
| 1.91 | < 0.01* | American | [ | |||
| ≥ 1.5 | < 0.05 | Chinese | [ | |||
| 5 | NDRG1 | Cytoplasmic protein belonging to the | 2.02 | 0.0001 | Japanese | [ |
| 2.67 | 1.12 × 10-5 | Caucasian | [ | |||
| 6 | BHLHE40 | Transcription factor with helix-loophelix | 1.95 | 0.0004 | Japanese | [ |
| 3.08 | 2.18 × 10-5 | Caucasian | [ | |||
| 7 | KRT19 | Keratin 19 | 1.75 | 0.0071 | Japanese | [ |
| 2.28 | 1.59 × 10-5 | Caucasian | [ | |||
| 8 | GPT2 | Alanine aminotransferase 2 | 2.45 | 3.70 × 10-5 | Caucasian | [ |
| 9 | PPP1R12C | 12A regulatory subunit of phosphatase | - | 2.16 × 10-8* | American | [ |
| 10 | CEBPA | CC AAT/enhancer-binding protein α | - | 2.52 × 10-8* | American | [ |
| 11 | HK2 | Type 2 hexokinase | 3.90 | 3.87 × 10-6 | Caucasian | [ |
| 12 | HMHA1 | Minor histocompatibility antigen HA1 | - | 1.23 × 10-8* | American | [ |
| 13 | PVRL4 | Nectin 4 | aaaa | aaaa | Caucasian | [ |
| 14 | SASH1 | SAM- and SH3-domain-containing | 2.54 | 1.22 × 10-7 | Caucasian | [ |
| 15 | SH3PXD2A | SH3- and PX-domain-containing | ≥ 1.5 | < 0.05 | Chinese | [ |
| 16 | SYDE1 | GTPase activating protein, homolog 1 | 1.55 | < 0.01* | American | [ |
* Significance level including multiple testing correction.